SHP626

DRUG3 trials

Sponsors

Mirum Pharmaceuticals, Inc.

Conditions

Non-Alcoholic Steatohepatitis

Phase 1

Safety and Tolerability Study of SHP626 in Overweight and Obese Adults

CompletedNCT02287779

Mirum Pharmaceuticals, Inc.Non-Alcoholic Steatohepatitis

Start: 2015-01-19End: 2015-06-19Updated: 2019-03-26

A Study to Investigate How the Study Drug SHP626 is Eliminated From the Body After One Dose

CompletedNCT02571192

Mirum Pharmaceuticals, Inc.Non-Alcoholic Steatohepatitis

Start: 2015-10-01End: 2015-10-01Updated: 2019-05-01

Phase 2

Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH)

TerminatedNCT02787304

Mirum Pharmaceuticals, Inc.Non-Alcoholic Steatohepatitis

Start: 2016-10-24End: 2018-07-27Updated: 2019-11-25

Related Papers

Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study.

2020-03-2961 citations

A randomised, double-blind, placebo-controlled phase 1 study of the safety, tolerability and pharmacodynamics of volixibat in overweight and obese but otherwise healthy adults: implications for treatment of non-alcoholic steatohepatitis

BMC Pharmacology and Toxicology2018-03-1630 citations

Absorption, Distribution, Metabolism, and Excretion of [14C]-Volixibat in Healthy Men: Phase 1 Open-Label Study

European Journal of Drug Metabolism and Pharmacokinetics2017-07-1214 citations